Leipzig/Römerberg: ROBOSCREEN GmbH and BIORON Diagnostics GmbH start a sales and development cooperation. Both companies develop and produce molecular diagnostic test and assays which are used by clinical routine laboratories.
ROBOSCREEN's focus is based on the viral load determination for management of chronic viral Hepatitis patients (such as Hepatitis-C, Hepatitis-B and Hepatitis-DELTA) as well as automated sample preparation systems.
BIORON supplies a great range of molecular diagnostic tests for mass infectious diseases like the Herpes virus panel, Respiratory infections, Human Papilloma viruses, Sexually Transmitted Infections and others.
“We are really happy about the partnership with BIORON”, Dr. Ingolf Lachmann, CEO of ROBOSCREEN says. “This collaboration allows us to greatly enlarge our portfolio by adding BIORON products which are of high quality, robust and very easy to use. This helps us us to become more attractive for prospect labs, to respond specifically to the wishes of existing customers and to offer flexible automated solutions additionally to the field of viral Hepatitis. Furthermore our partner BIORON Diagnostics can support acquiring new markets for our products which are not yet addressed by ROBOSCREEN”
Barbara Hassib, CEO of BIORON Diagnostics added: “BIORON Diagnostics will benefit from the automation possibilities ROBOSCREEN offers for high throughput demand of diagnostic labs. At the same time we get the possibility to introduce IvD-certified Hepatitis tests to our core markets and key accounts in combination with our own real-time PCR devices. This enables us to offer high-sensitive and reliable molecular diagnostic Hepatitis tests for management of chronic viral Hepatitis patients during therapy. We are looking forward for fruitful business with ROBOSCREEN.”
Both companies agreed to further validate & streamline their products together to offer IVDR-conform workflows for powerful combinations of ROBOSCREEN’s and BIORON Diagnostic’s products. This collaboration will highly increase performance and competitiveness for both companies.
